The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: An out-patient study

Rheumatology

Volumn 42, Issue 7, 2003, Pages 856-859

  Yee, C S ^e   Filer, A ^a   Pace, A ^b   Douglas, K ^c   Situnayake, D ^d   Rowe, Ian F ^a  

^a WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^c WALSGRAVE HOSPITAL   (United Kingdom)

^d CITY HOSPITAL   (United Kingdom)

^e The Guest Hospital   (United Kingdom)

Author keywords

Anti TNF therapy; BSR guidelines; Out patients; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; PREDNISOLONE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG USE; FEMALE; HUMAN; INFORMATION PROCESSING; LICENSING; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTPATIENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT FAILURE; UNITED KINGDOM; CLINICAL TRIAL; DRUG ANTAGONISM; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PATIENT SELECTION; RHEUMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GLUCOCORTICOIDS; GUIDELINE ADHERENCE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PATIENT SELECTION; PREDNISOLONE; PREVALENCE; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOLOGY; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141727782     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg231     Document Type: Article

References (17)

1. Albers JM, Kuper HH, van Riel PL et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology 1999;38:423-30.
2. McIntosh E. Clinical audit. The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
3. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
5. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841-50.
6. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
7. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
8. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
9. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
10. Lipsky PE, van de Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
11. Report of a working party of the British Society for Rheumatology. Guidelines for prescribing TNF blockers in adults with RA. BSR, available from www.rheumatology. org.uk April 2001.
12. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. NICE, March 2002.
13. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
14. Douglas K, Bowman SJ. How many patients are eligible for anti-TNF therapy in the. UK? Rheumatology 2001; 40:1416.
15. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612-9.
16. Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: a randomised controlled double blind 52 week clinical trial of sulphasalazine and methotrexate compared to single components. Ann Rheum Dis 1999;58:220-5.
17. Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Arthritis Rheum 2002;46:906-12.